- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07835048
The OSTIAL Study (Optimization of Stent Placement in Aorto-ostial Lesions) (OSTIAL)
Optimisation du Positionnement Des Stents Dans Les lésions Aorto-ostiales : étude Multicentrique Historico-prospective Avec Phase randomisée Comparant l'Angioplastie Coronaire Avec ou Sans Technique du Floating Ballon Étude OSTIAL (Optimizing Stent In Aorto-Ostial Lesion)
Aorto-ostial coronary lesions present a significant challenge during coronary angioplasty. This is due to the difficulty of precisely identifying the aorto-ostial plane and the frequent instability of the guiding catheter during stent deployment.
Despite the angiographic appearance being deemed optimal, several studies have shown a high rate of suboptimal stent positioning at the ostium when subsequent coronary CT angiography (CCTA) assessment is performed.
This suboptimal positioning may be linked to incomplete ostial coverage, which could increase the risk of in-stent restenosis. It may also be linked to excessive stent protrusion into the aorta, which could compromise future procedures, particularly in the context of transcatheter aortic valve replacement.
The "Floating Balloon" (FB) technique has been developed to improve system stability and to reliably mark the aorto-ostial landing zone (AOLZ). A previous study demonstrated the feasibility and accuracy of this technique.
The aim of the current study is to assess the clinical effectiveness of the Floating Balloon. Although this technique is already in use, no study has yet conducted a systematic assessment of stent positioning using CCTA.
The study utilised a combined retrospective-prospective approach to comprehensively evaluate the incidence of suboptimal stent positioning associated with the Floating Balloon technique. This evaluation was conducted by systematically comparing patient outcomes between those treated with the FB and those treated without the FB. The study employed CCTA as a key tool to assess stent position, ensuring a precise analysis of the data.
To achieve this, it is recommended that follow-up data from patients who have already undergone the FB procedure and had their stent position assessed via CCTA (retrospective component) be analysed, while also enrolling new patients and randomizing them into FB and non-FB groups (prospective component).
Panoramica dello studio
Stato
Descrizione dettagliata
In order to address the primary objective (namely, to estimate the rate of stent malpositioning), 97 evaluable subjects are required to achieve a precision (half-width of the 95% confidence interval) of +/-10% (assuming a conservative 50% rate of correct positioning).
As assessments are conducted immediately after the procedure, the investigators do not anticipate a significant number of non-evaluable subjects. The proposal is to enrol N=100 subjects in the FB group, with 50 subjects in the retrospective phase and another 50 in the prospective phase.
In order to address the secondary objective of comparing malpositioning rates between the two groups (with and without FB), patients in the non-FB group should be enrolled at a 1:2 ratio. The justification for this number is based on feasibility. This will provide preliminary data for the non-FB group.
Therefore, given our retrospective cohort of 50 FB subjects with available measurements, the prospective phase will include N=50 + 25-or 75 additional subjects (50 in the FB arm and 25 in the non-FB arm). The analyses will therefore cover a total of 125 subjects (100 with FB and 25 without FB).
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Frank FD DIGNE, PHD
- Numero di telefono: 01 49 33 41 13
- Email: f.digne@ccn.fr
Backup dei contatti dello studio
- Nome: Karima MOUSSOUNI, CRA
- Numero di telefono: 0679145144
- Email: k.moussouni@ccn.fr
Luoghi di studio
-
-
-
Bois-Bernard, Francia
- Hôpital privé Bois Bernard
-
Contatto:
- Sina POROUCHANI, Dr
- Numero di telefono: 0683575767
- Email: sina.porouchani@gmail.com
-
Clermont-Ferrand, Francia
- CHU Clermont-Ferrand
-
Contatto:
- Géraud SOUTEYRAND, Dr
- Numero di telefono: 0473751410
- Email: gsouteyrand@chu-clermontferrand.fr
-
Creil, Francia
- GHPSO Creil
-
Contatto:
- Salim SB BELGUIDOUM, Dr
- Numero di telefono: 0661332746
- Email: salim_0101@hotmail.fr
-
Massy, Francia
- Institut Cardiovasculaire Paris Sud - Massy
-
Contatto:
- Nicolas Amabile
- Numero di telefono: 0612523423
- Email: nicolasamabile@yahoo.fr
-
Saint-Denis, Francia
- Centre cardiologique du nord
-
Contatto:
- Frank FD DIGNE, PHD
- Numero di telefono: 01 49 33 41 13
- Email: f.digne@ccn.fr
-
Contatto:
- Karima KM MOUSSOUNI, Cra
- Numero di telefono: 0679145144
-
Sub-investigatore:
- Arthur AD DARMON, Dr
-
Saint-Etienne, Francia
- CHU de saint étienne
-
Contatto:
- Marouane BOUKHRIS, Dr
- Numero di telefono: 0650278487
- Email: marouaneboukhris1@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female aged over 18 years
- Prospective part: Patient who has signed an informed consent form
- Retrospective part: No objection to the use of personal data for this research
- Indication for coronary angioplasty for an aorto-ostial lesion (right coronary artery or left main coronary artery) for patients included in the prospective part / Patients in the historical part who underwent coronary angioplasty for an aorto-ostial lesion (right coronary artery or left main coronary artery) using the "floating balloon" (FB) technique, followed by a CCTA assessment of positioning
- Affiliation with or beneficiary of a social security scheme.
Exclusion Criteria:
- Contraindication to coronary CT angiography (severe renal impairment not requiring dialysis (GFR ≤ 30 ml/min)), applicable only to patients included in the prospective part
- Refusal of consent (patients included in the prospective part)
- Objection to the use of personal data (patients in the retrospective part)
- Patient unable to read, write, or understand French
- Vulnerable patient as defined by Article L1121-6 of the Public Health Code (CSP)
- Adult patient placed under guardianship, curatorship, or judicial protection
- Patient unable to personally provide consent pursuant to Article L.1121-8 of the CSP, or an adult under legal protection
- Pregnant or breastfeeding woman as defined by Article L1121-5 of the CSP
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Coronary angioplasty using the floating balloon technique
|
Coronary angioplasty using the FB technique involves the following steps:
|
|
Comparatore attivo: Coronary angioplasty without the floating-balloon technique
|
Angioplasty of the aorto-ostial lesion without the jailed-balloon (FB) technique will be performed as follows:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
The number of participants in whom stent placement was technically successful and who were evaluated by CT scan.
Lasso di tempo: At the end of the procedure
|
At the end of the procedure
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The secondary outcome is the rate of major adverse cardiovascular events (MACE).
Lasso di tempo: 12 months after the surgery procedure
|
The secondary outcome is the rate of major adverse cardiovascular events (MACE), including cardiac mortality, all-cause mortality, myocardial infarction (MI), target lesion revascularization (TLR) and hospitalisation for cardiovascular causes. |
12 months after the surgery procedure
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Frank FD DIGNE, PHD, Centre Cardiologique du Nord
Pubblicazioni e link utili
Pubblicazioni generali
- Dishmon DA, Elhaddi A, Packard K, Gupta V, Fischell TA. High incidence of inaccurate stent placement in the treatment of coronary aorto-ostial disease. J Invasive Cardiol. 2011 Aug;23(8):322-6.
- Digne F, Darmon A, Belguidoum S, Nejjari M, Feignoux J. Optimizing Stent Placement in Ostial Coronary Lesions With the Floating Balloon Technique: The OSTIAL (Optimizing Stent In Aorto-Ostial Lesion) Pivotal Study. Catheter Cardiovasc Interv. 2025 Apr;105(5):1269-1277. doi: 10.1002/ccd.31449. Epub 2025 Feb 17.
- Digne F, Darmon A, Nejjari M. Optimizing Stent Placement in Aorto-Ostial Lesions: Introducing the New Floating Balloon Technique. JACC Cardiovasc Interv. 2024 Sep 9;17(17):2082-2084. doi: 10.1016/j.jcin.2024.06.025. Epub 2024 Aug 21. No abstract available.
- Jaffe R, Halon DA, Shiran A, Rubinshtein R. Percutaneous treatment of aorto-ostial coronary lesions: Current challenges and future directions. Int J Cardiol. 2015;186:61-6. doi: 10.1016/j.ijcard.2015.03.161. Epub 2015 Mar 17.
- Yamamoto K, Sato T, Salem H, Matsumura M, Fall KN, Prasad M, Ng VG, Sethi SS, Nazif TM, Parikh SA, Vahl TP, Ali ZA, Karmpaliotis D, Rabbani LE, Collins MB, Leon MB, McEntegart MB, Moses JW, Kirtane AJ, Mintz GS, Maehara A. Mechanisms and treatment outcomes of ostial right coronary artery in-stent restenosis. EuroIntervention. 2023 Aug 7;19(5):e383-e393. doi: 10.4244/EIJ-D-23-00107.
- Freeman M, Clark DJ, Andrianopoulos N, Duffy SJ, Lim HS, Brennan A, Charter K, Shaw J, Horrigan M, Ajani AE, Sebastian M, Reid CM, Farouque HM; Melbourne Interventional Group. Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents. Catheter Cardiovasc Interv. 2009 May 1;73(6):763-8. doi: 10.1002/ccd.21941.
- Rubinshtein R, Ben-Dov N, Halon DA, Lavi I, Finkelstein A, Lewis BS, Jaffe R. Geographic miss with aorto-ostial coronary stent implantation: insights from high-resolution coronary computed tomography angiography. EuroIntervention. 2015 Jul;11(3):301-7. doi: 10.4244/EIJV11I3A57.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2026-A01154-47
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .